

20 October 2021

Sponsor: Millendo Therapeutics, Inc.
Protocol no.: ATR-101-301
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
EudraCT no.: 2016-002240-17

To whom it may concern:

The ATR-101-301 trial entitled "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome" was terminated early due to inability to enroll.